Moderna, Pfizer and COVID-19

Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open ...
Moderna says its long-running patent dispute with Pfizer and BioNTech isn't over even after a decision by an administrative ...
Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...
The police and fire-rescue departments partnered with the town manager’s office to guide the town’s COVID-19 response.
Moderna's COVID sales have been declining, and the company has been trimming costs. But it doesn't have a huge growth ...
Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...
A big legal victory across the Atlantic Ocean was the news propelling Moderna (NASDAQ: MRNA) stock to a significant price ...
The pandemic's volatility affected all public companies, but some saw their business deeply transformed. Here's how three of ...